Physician profile
Tamara Wright
NPI 1710911839
$6,360.56
in general payments reported to CMS, 2019-2025
31 companies · $824 in 2025
The $824 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,314 · 2022: $1,592 · 2023: $1,538 · 2024: $1,093 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,454.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,053.19 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $381.40 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $368.01 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Xeris Pharmaceuticals, INC. | $278.13 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $224.29 | 2021-2024 | |
| Tandem Diabetes Care, INC. | $209.46 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $187.26 | 2021-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Amgen INC. | $185.31 | 2021-2025 | Evenity, Prolia, Tepezza |
| Ascensia Diabetes Care US INC. | $182.21 | 2023 | |
| Insulet Corporation | $148.83 | 2021-2024 | Omnipod |
| Abbott Laboratories | $137.58 | 2022-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $122.65 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $122.65 | 2021-2022 | |
| Abbvie INC. | $120.92 | 2021-2025 | |
| Horizon Therapeutics Plc | $116.72 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $75.26 | 2021-2024 | Minimed 780g |
| Genzyme Corporation | $66.14 | 2022-2025 | |
| Radius Health, INC. | $60.09 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $47.11 | 2022-2023 | Steglatro, Steglujan, Belsomra |
| Corcept Therapeutics | $44.58 | 2023-2024 | Korlym |
| Novartis Pharmaceuticals Corporation | $40.89 | 2024 | |
| Zealand Pharma US, INC. | $23.52 | 2021 | |
| Ascendis Pharma Endocrinology INC | $22.99 | 2025 | Yorvipath |
| Clarus Therapeutics INC. | $19.32 | 2021 | |
| Antares Pharma, INC. | $18.92 | 2025 | Xyosted |
| Halozyme INC | $18.40 | 2023 | |
| Vistapharm, INC. | $18.12 | 2021 | |
| Amryt Pharma Holdings LTD | $17.25 | 2023 | Mycapssa |
| Ipsen Biopharmaceuticals, INC | $16.96 | 2021 | |
| Glaxosmithkline, LLC. | $16.91 | 2025 | Nucala |
| Pharming Healthcare, INC. | $15.49 | 2024 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.